Supportive Care and Scheduling for Sacituzumab Govitecan in Clinical Practice in Breast Cancer

In this section, the speakers focus on sacituzumab govitecan and the supportive care needs associated with its use. Dr Mouabbi explains that while the drug provides strong activity in heavily pretreated breast cancer, successful use in practice requires attention to toxicity patterns, particularly neutropenia. He notes that clinicians often delay the start of growth factor prophylaxis until neutropenia occurs, but evidence suggests that early prophylactic use can reduce treatment delays and interruptions.

The experts review differences in toxicity between sacituzumab govitecan and other ADCs. Sacituzumab govitecan is characterized by neutropenia and diarrhea, while datopotamab deruxtecan is more associated with mucositis and ocular irritation, and trastuzumab deruxtecan carries risk for interstitial lung disease. Understanding these distinctions allows clinicians to tailor supportive care for each agent and maintain treatment continuity.

They discuss the importance of monitoring schedules and emphasize that regular assessment helps clinicians adjust therapy appropriately. Dr Tarantino notes that community practices may require additional coordination with nursing and pharmacy teams to ensure that supportive care medications and infusion schedules are prepared well in advance.

This section also highlights the need for communication between clinicians and patients regarding expected side effects. When patients understand that neutropenia can be prevented or managed effectively, they are more willing to remain on treatment. The discussion reinforces the idea that early and consistent supportive care is central to achieving the best outcomes.

The speakers conclude that sacituzumab govitecan remains an important option for patients with metastatic breast cancer, but its safe use depends on proactive supportive care and careful planning. They emphasize that real world success with this drug relies as much on practical implementation as it does on clinical trial results.